Gregory L. Fricchione
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gregory L. Fricchione has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Elizabeth Broadbent
Department of Psychological Medicine, The University of Auckland, Auckland 1010, New Zealand
4 shared publications - John W. Denninger
Massachusetts General Hospital Boston, MA United States
4 shared publications - Kate Loveys
Department of Paediatrics: Child and Youth Health, School of Medicine University of Auckland Auckland New Zealand
4 shared publications - Mark Sagar
Soul Machines Ltd, Auckland, New Zealand
4 shared publications - Zeina Chemali
Henry and Allison McCance Center for Brain Health, Massachusetts General Hospital, Boston
4 shared publications - Herbert Benson
Benson-Henry Institute for Mind Body Medicine, Massachusetts General Hospital, 151 Merrimac St., Boston, MA 02114, USA
3 shared publications
Latest Publications
- 18 August 2025
- Published by Elsevier in Journal of the Academy of Consultation-Liaison Psychiatry
- Vol. 66 (6) , 562-563
In Memoriam: Max Fink MD 1923–2025
- 18 August 2025
- Published by Elsevier in Journal of the Academy of Consultation-Liaison Psychiatry
- Vol. 66 (6) , 562-563
In Memoriam: Max Fink MD 1923–2025
- 10 June 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (11) , e213674
Use of the Brain Care Score to Estimate the Risk of Incident Cerebrovascular Events in Middle-Aged Women
In the United States, stroke is the third leading cause of death among women, with 1 in 5 women aged 55 to 75 years expected to experience a stroke. The Brain Care Score (BCS) is an evidence-based tool designed to motivate lifestyle changes, with higher scores associated with reduced risk of stroke, dementia, and depression. We aim to measure the association of the BCS and incident cerebrovascular events (CVEs), including stroke and transient ischemic attack (TIA), in the Women's Health Study (WHS). The WHS comprises women health professionals aged 45 and older in the United States. Participants without history of CVE and complete data available to calculate a BCS and covariates 5 years after enrollment were included. Higher BCS reflects better risk factor control, with the minimum score being 0 and the maximum score being 20. Cox proportional hazard models examined the association between BCS and incident CVE adjusted for potential confounders. A total of 21,271 women were eligible with a median age of 57.9 years (interquartile range: 53.9-63.8) and median BCS of 15 (interquartile range [IQR]:13-16). There were 1,294 incident CVE cases (6.1%) during a median follow-up of 22.4 (IQR: 15.9-23.5) years. A five-point higher baseline BCS was associated with a 37% decrease in the risk of incident CVE after adjusting for age, menopausal status, use of hormonal replacement therapy, and other known cardiovascular disease risk factors (hazard ratio [HR] 0.63, 95% CI 0.56-0.71). This association remained significant after adjusting for race, educational attainment, and income (HR 0.64, 95% CI 0.57-0.72). There was a 28% decreased risk of incident CVE among those with a BCS equal to or above the median compared with those with a BCS below the median, in a fully adjusted model (HR 0.72, 95% CI 0.64-0.80). Higher baseline BCS was associated with a decreased risk of incident CVE in the WHS. Future studies are needed to study the BCS in more diverse populations and to investigate how changes in BCS across the lifespan affect risk of CVE.
- 10 June 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (11) , e213674
Use of the Brain Care Score to Estimate the Risk of Incident Cerebrovascular Events in Middle-Aged Women
In the United States, stroke is the third leading cause of death among women, with 1 in 5 women aged 55 to 75 years expected to experience a stroke. The Brain Care Score (BCS) is an evidence-based tool designed to motivate lifestyle changes, with higher scores associated with reduced risk of stroke, dementia, and depression. We aim to measure the association of the BCS and incident cerebrovascular events (CVEs), including stroke and transient ischemic attack (TIA), in the Women's Health Study (WHS). The WHS comprises women health professionals aged 45 and older in the United States. Participants without history of CVE and complete data available to calculate a BCS and covariates 5 years after enrollment were included. Higher BCS reflects better risk factor control, with the minimum score being 0 and the maximum score being 20. Cox proportional hazard models examined the association between BCS and incident CVE adjusted for potential confounders. A total of 21,271 women were eligible with a median age of 57.9 years (interquartile range: 53.9-63.8) and median BCS of 15 (interquartile range [IQR]:13-16). There were 1,294 incident CVE cases (6.1%) during a median follow-up of 22.4 (IQR: 15.9-23.5) years. A five-point higher baseline BCS was associated with a 37% decrease in the risk of incident CVE after adjusting for age, menopausal status, use of hormonal replacement therapy, and other known cardiovascular disease risk factors (hazard ratio [HR] 0.63, 95% CI 0.56-0.71). This association remained significant after adjusting for race, educational attainment, and income (HR 0.64, 95% CI 0.57-0.72). There was a 28% decreased risk of incident CVE among those with a BCS equal to or above the median compared with those with a BCS below the median, in a fully adjusted model (HR 0.72, 95% CI 0.64-0.80). Higher baseline BCS was associated with a decreased risk of incident CVE in the WHS. Future studies are needed to study the BCS in more diverse populations and to investigate how changes in BCS across the lifespan affect risk of CVE.
- Open Access
The Catatonia Quick Screen (CQS): A Rapid Screening Tool for Catatonia in Adult and Pediatric Populations
Introduction: Catatonia is a neuropsychiatric disorder marked by significant disturbances in motor, cognitive, and affective functioning and that is frequently under-diagnosed. To enhance clinical detection of catatonia, this study aimed to develop a rapid, sensitive Catatonia Quick Screen (CQS) using a reduced set of catatonic signs to facilitate screening in adult and pediatric patients. Methods: Data were derived from two retrospective cohorts totaling 446 patients (254 adults, 192 children) who screened positive for catatonia using the Bush Francis Catatonia Screening Instrument (BFCSI). Sensitivity analyses were performed for all combinations of BFCSI signs, with sensitivity defined as the proportion of patients identified by each subset relative to the full BFCSI. The CQS was developed by selecting signs from the BFCSI based on sensitivity, ease of assessment, and relevance to diverse catatonia presentations. Results: Screening for the presence of any one of four signs—excitement, mutism, staring, or posturing—using the CQS yielded a theoretical sensitivity of 97% (95% CI: 95 to 98%) relative to the full BFCSI (which requires two signs out of 14). The CQS demonstrated 97% sensitivity across both pediatric and adult subsets. Conclusion: The Catatonia Quick Screen provides a rapid screening alternative to the BFCSI with high sensitivity, potentially improving early detection of catatonia in clinical settings. Future prospective studies are necessary to validate the CQS’s sensitivity and to determine its specificity in clinical populations. Significant Outcomes: The Catatonia Quick Scale (CQS) is a newly developed rapid screen for catatonia. Assessment for any one of four signs—excitement, mutism, staring, and posturing—has 97% sensitivity for detecting catatonia relative to the BFCSI. This screening is sensitive in both adult and pediatric populations. Limitations: The study relies on retrospective data. Only patients who initially screened positive for catatonia were included, so the specificity of the CQS could not be assessed. Most of the sample has a primary psychiatric diagnosis so the generalizability to patients with primary medical disorders is unclear.
Open AccessThe Catatonia Quick Screen (CQS): A Rapid Screening Tool for Catatonia in Adult and Pediatric Populations
Introduction: Catatonia is a neuropsychiatric disorder marked by significant disturbances in motor, cognitive, and affective functioning and that is frequently under-diagnosed. To enhance clinical detection of catatonia, this study aimed to develop a rapid, sensitive Catatonia Quick Screen (CQS) using a reduced set of catatonic signs to facilitate screening in adult and pediatric patients. Methods: Data were derived from two retrospective cohorts totaling 446 patients (254 adults, 192 children) who screened positive for catatonia using the Bush Francis Catatonia Screening Instrument (BFCSI). Sensitivity analyses were performed for all combinations of BFCSI signs, with sensitivity defined as the proportion of patients identified by each subset relative to the full BFCSI. The CQS was developed by selecting signs from the BFCSI based on sensitivity, ease of assessment, and relevance to diverse catatonia presentations. Results: Screening for the presence of any one of four signs—excitement, mutism, staring, or posturing—using the CQS yielded a theoretical sensitivity of 97% (95% CI: 95 to 98%) relative to the full BFCSI (which requires two signs out of 14). The CQS demonstrated 97% sensitivity across both pediatric and adult subsets. Conclusion: The Catatonia Quick Screen provides a rapid screening alternative to the BFCSI with high sensitivity, potentially improving early detection of catatonia in clinical settings. Future prospective studies are necessary to validate the CQS’s sensitivity and to determine its specificity in clinical populations. Significant Outcomes: The Catatonia Quick Scale (CQS) is a newly developed rapid screen for catatonia. Assessment for any one of four signs—excitement, mutism, staring, and posturing—has 97% sensitivity for detecting catatonia relative to the BFCSI. This screening is sensitive in both adult and pediatric populations. Limitations: The study relies on retrospective data. Only patients who initially screened positive for catatonia were included, so the specificity of the CQS could not be assessed. Most of the sample has a primary psychiatric diagnosis so the generalizability to patients with primary medical disorders is unclear.
- Open Access
Effects of Aerobic Exercise on Brain Age and Health in Middle-Aged and Older Adults: A Single-Arm Pilot Clinical Trial
Backgrounds: Sleep disturbances are prevalent among elderly individuals. While polysomnography (PSG) serves as the gold standard for sleep monitoring, its extensive setup and data analysis procedures impose significant costs and time constraints, thereby restricting the long-term application within the general public. Our laboratory introduced an innovative biomarker, utilizing artificial intelligence algorithms applied to PSG data to estimate brain age (BA), a metric validated in cohorts with cognitive impairments. Nevertheless, the potential of exercise, which has been a recognized means of enhancing sleep quality in middle-aged and older adults to reduce BA, remains undetermined. Methods: We conducted an exploratory study to evaluate whether 12 weeks of moderate-intensity exercise can improve cognitive function, sleep quality, and the brain age index (BAI), a biomarker computed from overnight sleep electroencephalogram (EEG), in physically inactive middle-aged and older adults. Home wearable devices were used to monitor heart rate and overnight sleep EEG over this period. The NIH Toolbox Cognition Battery, in-lab overnight polysomnography, cardiopulmonary exercise testing, and a multiplex cytokines assay were employed to compare pre- and post-exercise brain health, exercise capacity, and plasma proteins. Results: In total, 26 participants completed the initial assessment and exercise program, and 24 completed all procedures. Data are presented as mean [lower 95% CI of mean, upper 95% CI of mean]. Participants significantly increased maximal oxygen consumption (Pre: 21.11 [18.98, 23.23], Post 22.39 [20.09, 24.68], mL/kg/min; effect size: −0.33) and decreased resting heart rate (Pre: 66.66 [63.62, 67.38], Post: 65.13 [64.25, 66.93], bpm; effect size: −0.02) and sleeping heart rate (Pre: 64.55 [61.87, 667.23], Post: 62.93 [60.78, 65.09], bpm; effect size: −0.15). Total cognitive performance (Pre: 111.1 [107.6, 114.6], Post: 115.2 [111.9, 118.5]; effect size: 0.49) was significantly improved. No significant differences were seen in BAI or measures of sleep macro- and micro-architecture. Plasma IL-4 (Pre: 0.24 [0.18, 0.3], Post: 0.33 [0.24, 0.42], pg/mL; effect size: 0.49) was elevated, while IL-8 (Pre: 5.5 [4.45, 6.55], Post: 4.3 [3.66, 5], pg/mL; effect size: −0.57) was reduced. Conclusions: Cognitive function was improved by a 12-week moderate-intensity exercise program in physically inactive middle-aged and older adults, as were aerobic fitness (VO2max) and plasma cytokine profiles. However, we found no measurable effects on sleep architecture or BAI. It remains to be seen whether a study with a larger sample size and more intensive or more prolonged exercise exposure can demonstrate a beneficial effect on sleep quality and brain age.
Open AccessEffects of Aerobic Exercise on Brain Age and Health in Middle-Aged and Older Adults: A Single-Arm Pilot Clinical Trial
Backgrounds: Sleep disturbances are prevalent among elderly individuals. While polysomnography (PSG) serves as the gold standard for sleep monitoring, its extensive setup and data analysis procedures impose significant costs and time constraints, thereby restricting the long-term application within the general public. Our laboratory introduced an innovative biomarker, utilizing artificial intelligence algorithms applied to PSG data to estimate brain age (BA), a metric validated in cohorts with cognitive impairments. Nevertheless, the potential of exercise, which has been a recognized means of enhancing sleep quality in middle-aged and older adults to reduce BA, remains undetermined. Methods: We conducted an exploratory study to evaluate whether 12 weeks of moderate-intensity exercise can improve cognitive function, sleep quality, and the brain age index (BAI), a biomarker computed from overnight sleep electroencephalogram (EEG), in physically inactive middle-aged and older adults. Home wearable devices were used to monitor heart rate and overnight sleep EEG over this period. The NIH Toolbox Cognition Battery, in-lab overnight polysomnography, cardiopulmonary exercise testing, and a multiplex cytokines assay were employed to compare pre- and post-exercise brain health, exercise capacity, and plasma proteins. Results: In total, 26 participants completed the initial assessment and exercise program, and 24 completed all procedures. Data are presented as mean [lower 95% CI of mean, upper 95% CI of mean]. Participants significantly increased maximal oxygen consumption (Pre: 21.11 [18.98, 23.23], Post 22.39 [20.09, 24.68], mL/kg/min; effect size: −0.33) and decreased resting heart rate (Pre: 66.66 [63.62, 67.38], Post: 65.13 [64.25, 66.93], bpm; effect size: −0.02) and sleeping heart rate (Pre: 64.55 [61.87, 667.23], Post: 62.93 [60.78, 65.09], bpm; effect size: −0.15). Total cognitive performance (Pre: 111.1 [107.6, 114.6], Post: 115.2 [111.9, 118.5]; effect size: 0.49) was significantly improved. No significant differences were seen in BAI or measures of sleep macro- and micro-architecture. Plasma IL-4 (Pre: 0.24 [0.18, 0.3], Post: 0.33 [0.24, 0.42], pg/mL; effect size: 0.49) was elevated, while IL-8 (Pre: 5.5 [4.45, 6.55], Post: 4.3 [3.66, 5], pg/mL; effect size: −0.57) was reduced. Conclusions: Cognitive function was improved by a 12-week moderate-intensity exercise program in physically inactive middle-aged and older adults, as were aerobic fitness (VO2max) and plasma cytokine profiles. However, we found no measurable effects on sleep architecture or BAI. It remains to be seen whether a study with a larger sample size and more intensive or more prolonged exercise exposure can demonstrate a beneficial effect on sleep quality and brain age.
- Open Access
Exploring the Trajectory of Catatonia in Neurodiverse and Neurotypical Pediatric Hospitalizations: A Multicenter Longitudinal Analysis
Objective: Catatonia is a neuropsychiatric disorder that occurs in pediatric patients with a range of associated medical, psychiatric, and neurodevelopmental disorders (NDDs). This study describes hospital care of pediatric catatonia patients and compares treatments for neurotypical patients and those with NDDs. Methods: Retrospective cohort study from 1/1/2018 to 6/1/2023 of two academic medical centers of patients aged 18 and younger with catatonia. Patients were retrospectively assessed using the clinical global impressions-improvement (CGI-I) by two independent reviewers. Results: One hundred sixty-five patients were hospitalized for catatonia, of whom 50.3% had an NDD. Median age was 15. One hundred sixty-four patients were treated with a benzodiazepine, with a median maximum 24-hour dose of 6 mg lorazepam-equivalents, which did not differ for patients with and without NDDs. Electroconvulsive therapy (ECT) was utilized in 14.5% of patients. Median length of medical hospitalization was 5 days and hospitalizations were longer in neurotypical patients than in patients with NDDs. In an ordinal regression model, the probability of observing at least “much improvement” (CGI < 3) was 88.3% (95% CI: 82.4% to 92.3%), with NDD diagnosis associated with a lower odds of clinical response. Conclusions: The probability of patients achieving a CGI-I score indicating at least “much improvement” was 88.3%. Administered benzodiazepine dose and ECT treatment were similar for all patients, but neurotypical patients had longer hospitalizations than those with NDDs and had a higher odds of a more favorable clinical response. Research under controlled conditions is needed to optimize and endure equitable catatonia treatment in youth.
Open AccessExploring the Trajectory of Catatonia in Neurodiverse and Neurotypical Pediatric Hospitalizations: A Multicenter Longitudinal Analysis
Objective: Catatonia is a neuropsychiatric disorder that occurs in pediatric patients with a range of associated medical, psychiatric, and neurodevelopmental disorders (NDDs). This study describes hospital care of pediatric catatonia patients and compares treatments for neurotypical patients and those with NDDs. Methods: Retrospective cohort study from 1/1/2018 to 6/1/2023 of two academic medical centers of patients aged 18 and younger with catatonia. Patients were retrospectively assessed using the clinical global impressions-improvement (CGI-I) by two independent reviewers. Results: One hundred sixty-five patients were hospitalized for catatonia, of whom 50.3% had an NDD. Median age was 15. One hundred sixty-four patients were treated with a benzodiazepine, with a median maximum 24-hour dose of 6 mg lorazepam-equivalents, which did not differ for patients with and without NDDs. Electroconvulsive therapy (ECT) was utilized in 14.5% of patients. Median length of medical hospitalization was 5 days and hospitalizations were longer in neurotypical patients than in patients with NDDs. In an ordinal regression model, the probability of observing at least “much improvement” (CGI < 3) was 88.3% (95% CI: 82.4% to 92.3%), with NDD diagnosis associated with a lower odds of clinical response. Conclusions: The probability of patients achieving a CGI-I score indicating at least “much improvement” was 88.3%. Administered benzodiazepine dose and ECT treatment were similar for all patients, but neurotypical patients had longer hospitalizations than those with NDDs and had a higher odds of a more favorable clinical response. Research under controlled conditions is needed to optimize and endure equitable catatonia treatment in youth.
- Open Access
Stress-Induced Failure of Embodied Cognition
We derive the classic Yerkes-Dodson effect of applied stress on real-world performance in a highly natural manner from fundamental assumptions on cognition and its dynamics, as constrained by the asymptotic limit theorems of information and control theories. We further examine how differences in an underlying cognitive probability model might associate with different expressions of psychopathology. Vulnerability to psychopathology is framed as a ratio of toxic stress in the context of 'noise' and uncertainty to resilience. A 'thin tailed' underlying distribution appears to characterize expression of 'ordinary' situational depression/anxiety symptoms induced by stress, while a 'fat tailed' underlying distribution appears to be associated with brain structure and function abnormalities leading to serious mental illness where symptoms are not only emerging in the setting of severe stress but may emerge in a highly punctuated manner at relatively lower levels of stress. A simple hierarchical optimization model explores the effects of environmental 'shadow price' constraints in buffering or aggravating the effects of stress. Extension of the underlying theory to other patterns of pathology, like immune disorders and premature aging, seems apt. Ultimately, the probability models studied here can be converted to new statistical tools for the analysis of observational and experimental data.
Open AccessStress-Induced Failure of Embodied Cognition
We derive the classic Yerkes-Dodson effect of applied stress on real-world performance in a highly natural manner from fundamental assumptions on cognition and its dynamics, as constrained by the asymptotic limit theorems of information and control theories. We further examine how differences in an underlying cognitive probability model might associate with different expressions of psychopathology. Vulnerability to psychopathology is framed as a ratio of toxic stress in the context of 'noise' and uncertainty to resilience. A 'thin tailed' underlying distribution appears to characterize expression of 'ordinary' situational depression/anxiety symptoms induced by stress, while a 'fat tailed' underlying distribution appears to be associated with brain structure and function abnormalities leading to serious mental illness where symptoms are not only emerging in the setting of severe stress but may emerge in a highly punctuated manner at relatively lower levels of stress. A simple hierarchical optimization model explores the effects of environmental 'shadow price' constraints in buffering or aggravating the effects of stress. Extension of the underlying theory to other patterns of pathology, like immune disorders and premature aging, seems apt. Ultimately, the probability models studied here can be converted to new statistical tools for the analysis of observational and experimental data.
- Open Access
- 9 November 2023
- Published by Springer Nature in Research Square
Stress-Induced Failure of Embodied Cognition
We derive the classic Yerkes-Dodson effect of applied stress on real-world performance in a highly natural manner from fundamental assumptions on cognition and its dynamics, as constrained by the asymptotic limit theorems of information and control theories. We further examine how differences in an underlying cognitive probability model might associate with different expressions of psychopathology. Vulnerability to psychopathology is framed as a ratio of toxic stress in the context of ‘noise’ and uncertainty to resilience. A ‘thin tailed’ underlying distribution appears to characterize expression of ‘ordinary’ situational depression/anxiety symptoms induced by stress, while a ‘fat tailed’ underlying distribution appears to be associated with brain structure and function abnormalities leading to serious mental illness where symptoms are not only emerging in the setting of severe stress but may emerge in a highly punctuated manner at relatively lower levels of stress. A simple hierarchical optimization model explores the effects of environmental ‘shadow price’ constraints in buffering or aggravating the effects of stress. Extension of the underlying theory to other patterns of pathology, like immune disorders and premature aging, seems apt. Ultimately, the probability models studied here can be converted to new statistical tools for the analysis of observational and experimental data.
- 9 November 2023
- Published by Springer Nature in Research Square
Open AccessStress-Induced Failure of Embodied Cognition
We derive the classic Yerkes-Dodson effect of applied stress on real-world performance in a highly natural manner from fundamental assumptions on cognition and its dynamics, as constrained by the asymptotic limit theorems of information and control theories. We further examine how differences in an underlying cognitive probability model might associate with different expressions of psychopathology. Vulnerability to psychopathology is framed as a ratio of toxic stress in the context of ‘noise’ and uncertainty to resilience. A ‘thin tailed’ underlying distribution appears to characterize expression of ‘ordinary’ situational depression/anxiety symptoms induced by stress, while a ‘fat tailed’ underlying distribution appears to be associated with brain structure and function abnormalities leading to serious mental illness where symptoms are not only emerging in the setting of severe stress but may emerge in a highly punctuated manner at relatively lower levels of stress. A simple hierarchical optimization model explores the effects of environmental ‘shadow price’ constraints in buffering or aggravating the effects of stress. Extension of the underlying theory to other patterns of pathology, like immune disorders and premature aging, seems apt. Ultimately, the probability models studied here can be converted to new statistical tools for the analysis of observational and experimental data.
- Open Access
- 25 August 2023
- Published by S. Karger AG in Psychotherapy and Psychosomatics
- Vol. 92 (4) , 208-210
Clinical Implications of Illness Denial
Patient delay, usually defined as waiting more than 3 months to seek medical care, may be seen as an attempt to resolve or postpone the crisis brought on by suspicion of severe illness with all its negative implications. Denial is frequently thought to be the primary defense responsible for patient delay [1]. Illness denial is usually diagnosed through a thorough history and clinical examination, sometimes supported by semi-structured interviews or survey instruments.Patierno and colleagues [2] have made an important contribution to the literature on illness denial with their scholarly systematic review of the clinical importance of this health behavior in the setting of multiple diseases. Key among their findings are the following conclusions. Illness denial is a relatively common condition impacting a host of health attitudes and behaviors and resulting in a continuum of health consequences. This continuum involves on one end a health benefit that accrues from the enhanced coping that such an adaptive denial of distressing uncertainty provides. Adaptive denial early after symptom onset can be an appropriate psychological adaptation that titrates a person’s stress level and aids in decision-making, resulting in presentation to the physician and adherence to recommendations. Adaptive denial can also be a health asset later in the course of a serious illness by dampening excessive health anxiety and thus mitigating the kind of toxic hyper-awareness that can promote symptomatology and iatrogenic complications. On the other end, excessive and prolonged illness denial can become maladaptive, delaying early diagnosis and treatment, impairing adherence, and disturbing self-monitoring and self-care later in the course, with clear adverse health outcomes.The authors also discuss the need to operationalize the definition, diagnosis, and severity of illness denial and suggest for this purpose the use of The Diagnostic Criteria for Psychosomatic Research (DCPR) revised version [3]. In the revised DCPR, illness denial is one of 14 psychosomatic syndromes, along with allostatic load, type A behavior, alexithymia, hypochondriasis, disease phobia, thanatophobia, health anxiety, persistent somatization, conversion symptoms, anniversary reaction, demoralization, irritable mood, and secondary somatic symptoms.Many factors may play a role in the spectrum of attitudes that relate to illness perception and treatment-seeking behavior [4]. The severity continuum of adaptive to maladaptive denial mentioned above exists within another continuum, that of illness awareness, which moves from hypochondriasis and disease phobia on the engagement/approach end through health anxiety, delay in seeking treatment, lack of adherence to medical advice, and finally illness denial on the disengagement/avoidance end of the spectrum. It has been speculated that early in acute symptom perception, being on the health anxiety side of the spectrum and not on the patient delay side aids in detection and may lead to health benefits related to early diagnosis and treatment. However, later in a more chronic illness course, if treatment has been provided and nevertheless symptoms secondary to hypochondriasis and disease phobia persist, there may be unnecessary distress that can lead to excess morbidity.This spectrum of responses to the threat of a severe illness diagnosis may shed light on the concept of adaptive versus maladaptive denial on the far end of disengaging avoidance. By the same token, there may be on the other side of the spectrum, adaptive somatic concern versus somatization, and illness behavior on the far end of engaging approach. More research in this area would be welcome.Use of denial-like processes by patients in the cognitive appraisal process, employed to assess the crisis of illness, is influenced by a variety of factors [5]. Risk factors for patient delay due to denial may include aspects of the medical and psychiatric history, socioeconomic and cultural status, recent loss experience and family history of severe illness, personal coping style, perceived meaning of symptoms, and fear response consequences.From a psychological perspective, denial is the process by which the mind defends itself against painful or threatening thoughts, feelings, perceptions, or information. For someone with a possible serious illness diagnosis, there are phases involved in the denial process, as the threatening meaning of one or more symptoms is gradually sculpted into a more acceptable reality [6].One way to understand denial in the context of a serious illness diagnosis is through the lens of emotion regulation [7, 8]. From this neurobiological perspective, when the reality of separation threat posed by a severe illness diagnosis triggers amygdalar activation, there may be intolerance of uncertainty leading to the stress response. An overwhelming or persistent stress response may become toxic. Coping will involve attempts to keep this energy-depleting, toxic stress in the tolerable stress zone [9].Many factors shape lifestyle, presentation of symptoms, access to patient care, interactions between patients and physicians, adherence to medical advice, and response to treatment [6]. Individual attitudes and behaviors related to health and disease are major components of clinical encounters. But even before patients make the decision to seek help from a physician, they must allow themselves to admit threatening uncertainty into their consciousness. This essentially becomes a public health education challenge that links up efforts to enhance health literacy and well-being in primary care. Once patients come to physician attention, developing effective ways for doctors to interact with patients and their families in these complex situations, where delay in seeking care advances the risk of maladaptive denial, is therefore an important goal.This is a challenging area because there is very little evidence that a “denial...
- 25 August 2023
- Published by S. Karger AG in Psychotherapy and Psychosomatics
- Vol. 92 (4) , 208-210
Open AccessClinical Implications of Illness Denial
Patient delay, usually defined as waiting more than 3 months to seek medical care, may be seen as an attempt to resolve or postpone the crisis brought on by suspicion of severe illness with all its negative implications. Denial is frequently thought to be the primary defense responsible for patient delay [1]. Illness denial is usually diagnosed through a thorough history and clinical examination, sometimes supported by semi-structured interviews or survey instruments.Patierno and colleagues [2] have made an important contribution to the literature on illness denial with their scholarly systematic review of the clinical importance of this health behavior in the setting of multiple diseases. Key among their findings are the following conclusions. Illness denial is a relatively common condition impacting a host of health attitudes and behaviors and resulting in a continuum of health consequences. This continuum involves on one end a health benefit that accrues from the enhanced coping that such an adaptive denial of distressing uncertainty provides. Adaptive denial early after symptom onset can be an appropriate psychological adaptation that titrates a person’s stress level and aids in decision-making, resulting in presentation to the physician and adherence to recommendations. Adaptive denial can also be a health asset later in the course of a serious illness by dampening excessive health anxiety and thus mitigating the kind of toxic hyper-awareness that can promote symptomatology and iatrogenic complications. On the other end, excessive and prolonged illness denial can become maladaptive, delaying early diagnosis and treatment, impairing adherence, and disturbing self-monitoring and self-care later in the course, with clear adverse health outcomes.The authors also discuss the need to operationalize the definition, diagnosis, and severity of illness denial and suggest for this purpose the use of The Diagnostic Criteria for Psychosomatic Research (DCPR) revised version [3]. In the revised DCPR, illness denial is one of 14 psychosomatic syndromes, along with allostatic load, type A behavior, alexithymia, hypochondriasis, disease phobia, thanatophobia, health anxiety, persistent somatization, conversion symptoms, anniversary reaction, demoralization, irritable mood, and secondary somatic symptoms.Many factors may play a role in the spectrum of attitudes that relate to illness perception and treatment-seeking behavior [4]. The severity continuum of adaptive to maladaptive denial mentioned above exists within another continuum, that of illness awareness, which moves from hypochondriasis and disease phobia on the engagement/approach end through health anxiety, delay in seeking treatment, lack of adherence to medical advice, and finally illness denial on the disengagement/avoidance end of the spectrum. It has been speculated that early in acute symptom perception, being on the health anxiety side of the spectrum and not on the patient delay side aids in detection and may lead to health benefits related to early diagnosis and treatment. However, later in a more chronic illness course, if treatment has been provided and nevertheless symptoms secondary to hypochondriasis and disease phobia persist, there may be unnecessary distress that can lead to excess morbidity.This spectrum of responses to the threat of a severe illness diagnosis may shed light on the concept of adaptive versus maladaptive denial on the far end of disengaging avoidance. By the same token, there may be on the other side of the spectrum, adaptive somatic concern versus somatization, and illness behavior on the far end of engaging approach. More research in this area would be welcome.Use of denial-like processes by patients in the cognitive appraisal process, employed to assess the crisis of illness, is influenced by a variety of factors [5]. Risk factors for patient delay due to denial may include aspects of the medical and psychiatric history, socioeconomic and cultural status, recent loss experience and family history of severe illness, personal coping style, perceived meaning of symptoms, and fear response consequences.From a psychological perspective, denial is the process by which the mind defends itself against painful or threatening thoughts, feelings, perceptions, or information. For someone with a possible serious illness diagnosis, there are phases involved in the denial process, as the threatening meaning of one or more symptoms is gradually sculpted into a more acceptable reality [6].One way to understand denial in the context of a serious illness diagnosis is through the lens of emotion regulation [7, 8]. From this neurobiological perspective, when the reality of separation threat posed by a severe illness diagnosis triggers amygdalar activation, there may be intolerance of uncertainty leading to the stress response. An overwhelming or persistent stress response may become toxic. Coping will involve attempts to keep this energy-depleting, toxic stress in the tolerable stress zone [9].Many factors shape lifestyle, presentation of symptoms, access to patient care, interactions between patients and physicians, adherence to medical advice, and response to treatment [6]. Individual attitudes and behaviors related to health and disease are major components of clinical encounters. But even before patients make the decision to seek help from a physician, they must allow themselves to admit threatening uncertainty into their consciousness. This essentially becomes a public health education challenge that links up efforts to enhance health literacy and well-being in primary care. Once patients come to physician attention, developing effective ways for doctors to interact with patients and their families in these complex situations, where delay in seeking care advances the risk of maladaptive denial, is therefore an important goal.This is a challenging area because there is very little evidence that a “denial...
- Top Cited PapersOpen Access
- 30 March 2023
- Published by Springer Nature in BioPsychoSocial Medicine
- Vol. 17 (1) , 1-25
Mind body medicine: a modern bio-psycho-social model forty-five years after Engel
- 30 March 2023
- Published by Springer Nature in BioPsychoSocial Medicine
- Vol. 17 (1) , 1-25
Top Cited PapersOpen AccessMind body medicine: a modern bio-psycho-social model forty-five years after Engel